Research Article

Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia

Published: February 10, 2012
Genet. Mol. Res. 11 (1) : 317-321 DOI: https://doi.org/10.4238/2012.February.10.2
Cite this Article:
H.H. Hsiao, Y.C. Liu, C.P. Lee, C.S. Chang, S.F. Lin (2012). Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia. Genet. Mol. Res. 11(1): 317-321. https://doi.org/10.4238/2012.February.10.2
2,242 views

Abstract

Chromosome evolution is one of the major mechanisms of disease progression and resistance in chronic myeloid leukemia (CML) patients. However, the clinical significance of chromosomal evolution in the Philadelphia (Ph)-negative clone during therapy is not fully understood. We evaluated 94 CML patients in the chronic phase of CML during treatment of the disease. Six of them had Ph-negative chromosome abnormalities during treatment. Four patients with a single abnormality and a good molecular response showed no obvious complications from the chromosomal changes, while two other patients who had complex abnormalities and previous treatment had poor outcomes. Our results highlight the need for close monitoring of this kind of patient, not only on a molecular level but also at the cytogenetic level.

Chromosome evolution is one of the major mechanisms of disease progression and resistance in chronic myeloid leukemia (CML) patients. However, the clinical significance of chromosomal evolution in the Philadelphia (Ph)-negative clone during therapy is not fully understood. We evaluated 94 CML patients in the chronic phase of CML during treatment of the disease. Six of them had Ph-negative chromosome abnormalities during treatment. Four patients with a single abnormality and a good molecular response showed no obvious complications from the chromosomal changes, while two other patients who had complex abnormalities and previous treatment had poor outcomes. Our results highlight the need for close monitoring of this kind of patient, not only on a molecular level but also at the cytogenetic level.